NUMD · Nu-Med Plus, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Our financial statements have been prepared assuming that we will continue as a going concern, and our recurring losses, negative cash flows, and capital needs raise substantial doubt about our ability to continue our operations. We have incurred recurring losses from operations and have an accumulated deficit of approximately $9,945,722 and negative working capital of $267,486 as of June 30, 2026. Our independent registered public accounting firm has included an explanatory paragraph in its report on our financial statements for the year ended December 31, 2025, expressing substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to raise substantial additional capital, generate sufficient revenue, and manage our expenses, none of which can be assured.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| — | — | -$5000 | -$1000 | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $66.21K | $22.13K | |
| $23.12K | $34.32K | $27.56K | $26.57K | $32.28K | $58.26K | $76.13K | $128.1K | $64.97K | $62.17K | $34.88K | $60.17K | $20.54K | $13.4K | |
| — | — | — | $2267 | $9365 | $11.79K | $13.37K | $14.74K | $12.54K | $7148 | $7149 | $6964 | $3195 | $1817 | |
| $48.96K | $63.33K | $120.53K | $182.17K | $839.45K | $1.99M | $1.02M | $1.17M | $466.52K | $1.22M | $946.48K | $1.15M | $233.64K | $258.23K | |
| -$48.96K | -$63.33K | -$120.53K | -$182.17K | -$839.45K | -$1.99M | -$1.02M | -$1.17M | -$466.52K | -$1.22M | -$946.48K | -$1.15M | -$233.64K | -$258.23K | |
| — | — | — | -$179.9K | -$830.08K | -$1.98M | -$1.01M | -$1.15M | -$453.98K | -$1.22M | -$939.33K | -$1.14M | -$230.44K | -$256.41K | |
| $7227 | $5014 | $5000 | $1000 | — | $14.32K | $17.41K | -$19.54K | -$18.88K | -$15.91K | -$15.91K | -$46.62K | -$98.66K | -$4535 | |
| — | — | — | — | — | $0 | $11 | $101 | $122 | $7 | $7 | $13 | $1 | $18 | |
| -$7227 | -$5014 | -$5000 | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $3000 | — | — | — | — | — | — | — | — | — | — | |
| -$56.18K | -$68.35K | -$125.53K | -$130.17K | -$830.06K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $0 | $100 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$56.18K | -$68.35K | -$125.53K | -$130.17K | -$830.06K | -$2.01M | -$1.04M | -$1.19M | $3.58M | $9.65M | -$8.88M | -$1.19M | -$332.29K | -$262.74K | |
| USD/shares | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.04 | -$0.02 | -$0.03 | $0.10 | $0.26 | -$0.25 | — | — | — |
| USD/shares | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.04 | -$0.02 | -$0.03 | $0.05 | $0.13 | -$0.25 | — | — | — |
| shares | 83.55M | 83.55M | 81.67M | 79.95M | 73.37M | 54.51M | 45.55M | 41.79M | 37.46M | 37.22M | 35.4M | 32.79M | 27.82M | 22.64M |
| shares | 83.55M | 83.55M | 81.67M | 79.95M | 73.37M | 54.51M | 45.55M | 41.79M | 71.86M | 75.03M | 35.4M | — | — | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2026-06-30 | USD 100,000 | 10-Q filed 2026-08-14 |
| Noncurrent debt carrying amount | 2026-06-30 | USD 0 | 10-Q filed 2026-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 36 similar-size Medical Devices companies (of 150 listed).